Major 10% Investor Files Intent to Sell Additional $872K in Tenaya Therapeutics Stock
TNYA sits 73% above its 52-week low of $0.36.
Summary
COLUMN GROUP III, LP, a 10% stockholder, has filed a Form 144 indicating intent to sell approximately $872,538 worth of Tenaya Therapeutics common stock, continuing a pattern of distribution by this investor group.
Key Events · Ownership and Investor Activity · TNYA
-
Major Investor Files New Intent to Sell
COLUMN GROUP III, LP, a 10% stockholder, has filed a Form 144 to sell 1,408,910 shares of common stock, valued at approximately $872,538.
-
Ongoing Distribution by Column Group
This filing continues a pattern of distribution by The Column Group and its affiliates. The filer, COLUMN GROUP III, LP, has already sold 2,066,537 shares for gross proceeds of $1,428,738.78 in the past three months, in addition to other sales by related entities.
Analysis · TNYA · Life Sciences
COLUMN GROUP III, LP, a 10% stockholder, has filed a Form 144 indicating intent to sell approximately $872,538 worth of Tenaya Therapeutics common stock. This action is part of a consistent pattern of distribution by The Column Group and its affiliates, who have reported over $3 million in actual sales in recent weeks and multiple Form 144 filings for planned dispositions. The ongoing reduction of a significant institutional investor's stake can signal a lack of conviction or a need for liquidity, potentially creating an overhang on the stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.1M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.